Two-dose Primary Vaccination With Either GSK Biologicals' 10-valent Pneumococcal Vaccine (Synflorix) or Pfizer's Prevenar 13 or Both Vaccines Followed by a Booster Dose of Synflorix
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions; Registrational
- 29 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Sep 2013 Planned end date changed from 1 May 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 12 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.